ADDED
As of March 26, 2026, there were 6,406,191 shares of the registrant s common stock, $ 0.0001 par value, outstanding.
In addition, we continue to engage with the United States Food and Drug Administration ( FDA ) to keep the MAT2203 Investigational New Drug Application ( IND ) active and are actively maintaining and prosecuting intellectual property relating to MAT2203 and to the LNC Platform generally as well as maintaining all of our obligations under our license agreement with Rutgers University.
As a result of the reduction in force, we have paused the internal development of a pipeline of products utilizing the LNC Platform as we evaluate strategic alternatives for those early-stage programs in oncology and inflammatory diseases.
There can be no assurance that we will be successful in consummating a transaction involving MAT2203.
Corporate Events In February 2024, we announced agreement with the FDA on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive aspergillosis who have limited treatment options, including consensus on all critical elements of the ORALTO trial.
On April 2, 2024, we announced entry into a securities purchase agreement (the April 2024 Purchase Agreement ), with certain institutional investors.
The April 2024 Purchase Agreement provided for the sale and issuance by the Company of (i) 666,667 shares of common stock and warrants (the April 2024 Warrants ) to purchase up to 666,667 shares of common stock.
The offering price per share and accompanying warrant was $15.00.
The April 2024 Warrants have an exercise price of $17.50, were exercisable beginning October 2, 2024 and expire on the five-and-a-half year anniversary of the date of issuance, or October 5, 2029.
2 On August 20, 2024, pursuant to the NYSE American s Compliance Guidance Memo which requires ten calendar days public notice for certain corporate actions, we announced that our Board of Directors (the Board ) approved a reduction in the total number of authorized shares of our common stock from 500,000,000 to 250,000,000 (the Authorized Share Reduction ) and a reverse stock split of the common stock at a ratio of one-for-fifty (1:50) (the Reverse Stock Split ), which would become effective at 5:00PM (EST) on August 30, 2024.
REMOVED
As of April 15, 2025, there were 5,086,985 shares of the registrant s common stock, $ 0.0001 par value, outstanding.
In addition, the Company continues to engage with the FDA to keep the MAT2203 Investigational New Drug Application ( IND ) active and is actively maintaining and prosecuting intellectual property relating to MAT2203 and to the LNC Platform generally as well as maintaining all of its obligations under our license agreement with Rutgers University.
As a result of the reduction in force, the Company has paused the internal development of a pipeline of products utilizing the LNC Platform as it evaluates strategic alternatives for those early-stage programs in oncology and inflammatory diseases.
There can be no assurance that the Company will be successful in consummating a transaction involving MAT2203.
Corporate Events On September 21, 2023, Matinas Biopharma Holdings, Inc.
On November 1, 2023, at the 2023 annual meeting of stockholders of the Company, the stockholders approved the authorization of the Board of Directors (the Board ), in its sole and absolute discretion and without further stockholder approval, to (i) reduce the total number of authorized shares of the Company s Common Stock, from 500,000,000 to 250,000,000 (the Authorized Share Reduction ), and (ii) effect a reverse stock split of the Common Stock at a ratio to be determined by the Board ranging from a ratio of one-for-two (1:2) to a ratio of one-for-fifty (1:50).
In February 2024, we announced agreement with the United States Food and Drug Administration ( FDA ) on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive aspergillosis who have limited treatment options, including consensus on all critical elements of the ORALTO trial.
On April 2, 2024, we announced entry into a securities purchase agreement (the April 2024 Purchase Agreement ), with certain institutional investors (collectively, the April 2024 Purchasers ).
The April 2024 Purchase Agreement provided for the sale and issuance by the Company of (i) 666,667 shares (the April 2024 Shares ) of the Company s common stock, $0.0001 par value per share (the April 2024 Common Stock ) and warrants to purchase up to 666,667 shares of Common Stock (the Warrants and, together with the April 2024 Common Stock, the April 2024 Securities ).
The offering price per share and accompanying warrants was $15.00.